eLaws | eCases | United States Code | Federal Courts |

Bristol-Myers Squibb Company - Comment

Document ID: FDA-2008-D-0470-0006
Document Type: Public Submission
Agency: Food And Drug Administration
Received Date: October 16 2008, at 03:27 PM Eastern Daylight Time
Date Posted: October 17 2008, at 12:00 AM Eastern Standard Time
Comment Start Date: September 3 2008, at 12:00 AM Eastern Standard Time
Comment Due Date: October 20 2008, at 11:59 PM Eastern Standard Time
Tracking Number: 80761ab6
View Document:

This is comment on Notice

International Conference on Harmonisation; Draft Guidance on M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals; Availability

Attachments:

Bristol-Myers Squibb Company - Comment

Title:
Bristol-Myers Squibb Company - Comment

View Attachment:

View as format pdf

Related Comments

View All

Total: 9

Novo Nordisk Inc. - Comment
Public Submission Posted: 10/15/2008 ID: FDA-2008-D-0470-0003

Comment Period Closed
Oct 20,2008 11:59 PM ET

Eli Lilly and Company - Comment
Public Submission Posted: 10/16/2008 ID: FDA-2008-D-0470-0004

Comment Period Closed
Oct 20,2008 11:59 PM ET

Sanofi-aventis - Comment
Public Submission Posted: 10/17/2008 ID: FDA-2008-D-0470-0005

Comment Period Closed
Oct 20,2008 11:59 PM ET

Bristol-Myers Squibb Company - Comment
Public Submission Posted: 10/17/2008 ID: FDA-2008-D-0470-0006

Comment Period Closed
Oct 20,2008 11:59 PM ET

AstraZeneca - Comment
Public Submission Posted: 10/20/2008 ID: FDA-2008-D-0470-0007

Comment Period Closed
Oct 20,2008 11:59 PM ET